However, it was realized that the celecoxib concentrations achievable in patients were of the order of 3 μmol/l [27], whereas 50 μmol/l or greater is required to inhibit Akt activation in prostate [28] and breast cancer cells (Kucab and coworkers, unpublished data). The gene discussed is AKT1; the disease is breast cancer.